4月22日,石药集团(01093)发布公告,宣布其附属公司上海津曼特生物科技有限公司自主研发的抗体药物JMT203已获得美国食品药品监督管理局(FDA)批准,可以在美国开展临床研究。
JMT203是一种抗GDNF家族受体蛋白(GFRAL)重组人源化单克隆抗体,能够有效拮抗GDF15-GFRAL/RET信号,具有食欲和代谢调节作用,可潜在逆转或减轻由肿瘤及化疗药物引起的体重降低、厌食和肌肉萎缩。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.